Therapeutic Area | MeSH |
---|---|
eye diseases | D005128 |
immune system diseases | D007154 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
BEPREVE | Bausch Health Companies | N-022288 RX | 2009-09-08 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
bepotastine besilate | ANDA | 2024-10-10 |
bepotastine besilate ophthalmic solution 1.5% | ANDA | 2023-07-21 |
bepreve | New Drug Application | 2022-08-31 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
allergic conjunctivitis | EFO_0007141 | D003233 | H10.44 |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Bepotastine Besilate, Bepreve, Bausch And Lomb Inc | |||
8784789 | 2025-01-13 | DP |
Drug common name | Bepotastine |
INN | bepotastine |
Description | Bepotastine (Talion, Bepreve) is a 2nd generation antihistamine. It was approved in Japan for use in the treatment of allergic rhinitis and urticaria/pruritus in July 2000, and January 2002, respectively. It is marketed in the United States as an eye drop under the brand name Bepreve, by ISTA Pharmaceuticals, a subsidiary of Bausch + Lomb.
|
Classification | Small molecule |
Drug class | antihistaminics (histamine-H1 receptor antagonists) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | O=C(O)CCCN1CCC(O[C@@H](c2ccc(Cl)cc2)c2ccccn2)CC1 |
PDB | — |
CAS-ID | 125602-71-3 |
RxCUI | — |
ChEMBL ID | CHEMBL1201758 |
ChEBI ID | 71204 |
PubChem CID | 2350 |
DrugBank | DB04890 |
UNII ID | HYD2U48IAS (ChemIDplus, GSRS) |